Author Archives: Steve Bryson PhD

Hip surgery complications increase hospital stays, costs for AS patients

Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients after the surgery, according to an analysis of hospital records. More complications, including anemia and infections, soon after surgery drove these increases in stays and admission-related costs, researchers noted. These…

New Inflammation Biomarker May Be Useful in AS, Study Suggests

The ratio of two blood proteins, fibrinogen and albumin, accurately measures inflammation severity with different types of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study showed. The accuracy of this biomarker closely matched those of standard inflammatory markers used in research and clinical practice. Further studies are needed to…

Long-standing Link Between AS and HLA-B27 Explained

Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…

Bimekizumab Shows Symptom Improvements in Phase 3 Trials

One year of UCB Biopharm‘s investigational therapy bimekizumab, administered subcutaneously (under the skin) once every four weeks, resulted in sustained improvement in the signs and symptoms of axial spondyloarthritis (axSpA), according to late-breaking data from two BE MOBILE Phase 3 clinical trials. axSpA is a type of inflammatory…

Restarting Taltz After Withdrawal Reduces axSpA Activity: Trial Data

Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after restarting the therapy, according to data from a Phase 3 withdrawal study. The majority (71%) reached a state of disease remission after restarting treatment. These findings provide important information about…

Bimekizumab Now Under Review in Europe for Axial Spondyloarthritis

The European Medicines Agency has agreed to review UCB’s applications seeking the approval of bimekizumab for adults with active axial spondyloarthritis (axSpA). Axial spondyloarthritis is a type of inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is a severe type of axSpA,…

AS Led to Rare Ankle, Foot Bone Fusion for Man, 69: Case Study

Ankylosing spondylitis (AS) led to bone formation that resulted in the rare complete fusion of ankle and foot bones in a 69-year-old man, a case study reported. His AS was discovered only after hospitalization for kidney problems and an examination for gout. The researchers suggested the terminology “boot sign”…

Blood Levels of GM-CSF Rise With Disease Activity in AS Patients

High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS) and strongly correlated with disease activity, a pilot study suggested. Despite helping to lower disease activity, anti-TNF therapies did not affect GM-SCF levels. As such, GM-SCF may represent a…